GH Research (NASDAQ:GHRS) Upgraded at Cantor Fitzgerald

GH Research (NASDAQ:GHRS) was upgraded by equities research analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for GH Research’s FY2025 earnings at ($0.84) EPS.

Other research analysts also recently issued reports about the company. Royal Bank of Canada began coverage on GH Research in a research note on Friday, March 7th. They set an “outperform” rating and a $31.00 price target on the stock. Stifel Nicolaus upped their price target on GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Guggenheim dropped their price target on GH Research from $32.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of GH Research in a report on Friday, May 9th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $30.43.

GH Research Stock Performance

GHRS stock opened at $9.98 on Tuesday. The stock’s 50 day simple moving average is $10.28 and its 200 day simple moving average is $9.89. GH Research has a fifty-two week low of $6.00 and a fifty-two week high of $20.50. The company has a market cap of $519.24 million, a P/E ratio of -12.63 and a beta of 0.86.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.42. Equities analysts predict that GH Research will post -0.8 earnings per share for the current year.

Institutional Trading of GH Research

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GHRS. BNP Paribas Financial Markets bought a new stake in GH Research during the 4th quarter worth approximately $44,000. Two Sigma Investments LP bought a new position in shares of GH Research in the fourth quarter valued at approximately $117,000. Palumbo Wealth Management LLC bought a new position in shares of GH Research in the first quarter valued at approximately $142,000. Millennium Management LLC bought a new position in shares of GH Research in the fourth quarter valued at approximately $145,000. Finally, XTX Topco Ltd bought a new position in shares of GH Research in the first quarter valued at approximately $169,000. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).